For the Quarter Ending March 2026
听
Carbamazepine Prices in听North America
- In the United States, the Carbamazepine Index rose quarter-over-quarter, supported by steady pharmaceutical demand and tighter import inflows from Asia.
- The average level for the quarter reflected stable procurement from formulation manufacturers and hospital networks, driven by consistent prescription activity.
- Spot movement firmed as production cost trends increased due to higher energy expenses and stricter FDA compliance requirements across API facilities.
- Demand outlook remained stable to firm, supported by neurological treatment needs and consistent insurance-backed healthcare procurement cycles.
- Forward outlook indicates continued firmness as distributors maintained conservative inventory coverage amid longer import lead times.
- Inventory coverage stayed moderate but slightly tight, with roughly three to five weeks of demand available across key distribution hubs.
- Higher freight costs and regulatory documentation requirements increased landed cost pressure, supporting firmer ex-works offers from exporters.
- Reduced arbitrage from Asian suppliers, due to strong domestic demand in exporting regions, supported overall price stability.
Why did it change in March 2026 in North America?
- Strong prescription demand and steady hospital procurement reduced excess stock levels, tightening near-term availability.
- Elevated shipping costs and longer import lead times increased landed values, prompting firmer offer levels.
- Stricter regulatory checks and compliance delays reduced import flow efficiency, limiting rapid replenishment.
听
Carbamazepine Prices in听APAC
- In India, the Carbamazepine Price Index rose by 2.61% quarter-over-quarter, driven by tighter supply levels.
- The average Carbamazepine price for the quarter was approximately USD 36629.12/MT, reflecting production and exports.
- Carbamazepine Spot Price rose as Carbamazepine Production Cost Trend tightened from higher pet-coke and compliance.
- Carbamazepine Demand Outlook stayed robust, supporting Price Index via Jan Aushadhi tenders and formulation purchases.
- Carbamazepine Price Forecast indicates firmness as exporters pre-book shipments amid port congestion and limited stocks.
- Carbamazepine Price Index showed constrained availability; inventories covered three to four weeks for export commitments.
- Feedstock logistics and higher pet-coke-fired steam costs pressured margins, influencing producer pricing and breakeven levels.
- Strong export demand from the United States and Brazil reduced arbitrage, supporting firm ex-works offers
Why did the price of Carbamazepine change in March 2026 in APAC?
- Zero Liquid Discharge retrofits temporarily cut Gujarat throughput, tightening supply and prompting higher ex-works offers.
- Elevated export call-offs and pre-bookings consumed available inventories, accelerating demand and limiting downward price flexibility.
- Port delays and higher pet-coke steam costs raised input expenses, narrowing margins and justifying a price reset.
听
Carbamazepine Prices in听Europe
- In Europe, the Carbamazepine Index rose quarter-over-quarter, supported by tighter import availability and stable pharmaceutical consumption.
- The average level for the quarter reflected constrained supply across EU distribution channels, with steady healthcare-driven procurement patterns.
- Spot movement strengthened as production cost trends increased due to higher energy prices and environmental compliance expenses.
- Demand outlook remained stable, supported by chronic neurological treatment requirements and consistent public healthcare procurement.
- Forward outlook indicates continued firmness as longer shipping cycles and import dependence restrict rapid replenishment.
- Inventory levels remained moderately tight, with coverage typically limited to three to four weeks across major warehouses.
- Carbon pricing and stricter environmental regulations increased manufacturing costs, supporting firmer offer levels from regional producers.
- Reduced arbitrage opportunities from Asian suppliers reinforced price stability due to strong domestic demand in exporting regions.
Why did it change in March 2026 in Europe?
- Higher energy and compliance costs increased production expenses, tightening overall supply conditions.
- Stable hospital procurement and government healthcare programs reduced excess inventory build-up.
- Longer import lead times and shipping constraints limited replenishment speed, keeping availability tight and supporting firm sentiment.
For the Quarter Ending December 2025
听
Carbamazepine Price in North America
- In North America, the Carbamazepine Price Index declined quarter-over-quarter, reflecting adequate importer inventories and muted prescription-led procurement.
- The average Carbamazepine price for the quarter was estimated at approximately USD 37,900/MT, reflecting CFR transactional assessments.
- Carbamazepine Spot Prices remained under pressure as distributors relied on previously secured contracts and delayed incremental purchases.
- The Carbamazepine Production Cost Trend edged higher, driven by upstream solvent and compliance-related cost pass-through from exporters.
- Carbamazepine Demand Outlook stayed cautious, as hospitals and wholesalers focused on inventory optimization rather than expansionary buying.
- The Carbamazepine Price Forecast pointed toward continued softness, barring renewed tender activity or unexpected supply tightening.
- Comfortable inventory coverage across major distribution hubs capped upside and restrained the Carbamazepine Price Index.
- Stable import flows ensured supply continuity, limiting volatility despite cost-side pressures.
Why did the price of Carbamazepine change in December 2025 in North America?
- Elevated distributor inventories reduced procurement urgency, weakening near-term pricing support.
- Higher upstream production and compliance costs were partially reflected in offers but failed to offset subdued demand.
- Consistent import availability prevented supply tightness, sustaining a soft pricing environment through December.
听
Carbamazepine Price in APAC
- In India, the Carbamazepine Price Index fell by 13.65% quarter-over-quarter, reflecting inventory-driven surplus and subdued demand.
- The average Carbamazepine price for the quarter was approximately USD 35696.41/MT, reflecting muted demand and production.
- Producers passed through higher solvent-driven costs, lifting the Carbamazepine Production Cost Trend modestly during December.
- Export call-offs and Jan Aushadhi purchases firmed availability, supporting the Carbamazepine Spot Price in December.
- Inventory builds at downstream formulators capped upside, pressuring the Carbamazepine Price Index through this quarter.
- High plant run-rates and compliance outages tightened supply, informing the Carbamazepine Demand Outlook near term.
- Port congestion and longer dwell times constrained shipments, validating the Carbamazepine Price Forecast for easing.
- Producers absorbed effluent treatment costs, maintaining output to satisfy export demand, stabilizing the Price Index.
Why did the price of Carbamazepine change in December 2025 in APAC?
- Elevated solvent and acetic acid costs increased variable production expenses, exerting upward pressure on domestic pricing.
- Port dwell-time lengthening and intermittent west-coast congestion delayed exports, tightening spot availability during December.
- Sustained export call-offs and Jan Aushadhi procurement sustained offtake, enabling producers to pass on incremental costs.
听
Carbamazepine Price in Europe
- In Europe, the Carbamazepine Price Index softened quarter-over-quarter, reflecting slower public healthcare procurement and sufficient importer stocks.
- The average Carbamazepine price for the quarter was assessed at approximately USD 38,600/MT, based on distributor-level market indications.
- Carbamazepine Spot Prices remained range-bound, as buyers adopted hand-to-mouth purchasing strategies.
- The Carbamazepine Production Cost Trend showed mild upward pressure, driven by solvent pricing and environmental compliance expenses.
- Carbamazepine Demand Outlook weakened, with year-end budget discipline limiting new tenders across several markets.
- The Carbamazepine Price Forecast indicated limited recovery potential, unless post-quarter restocking resumes.
- Adequate warehouse inventories across Western Europe kept the Carbamazepine Price Index under pressure.
- Importers prioritized contract volumes over spot buying, maintaining stable but subdued market activity.
Why did the price of Carbamazepine change in December 2025 in Europe?
- Slower public-sector procurement reduced spot demand and dampened pricing momentum.
- Rising production and compliance costs provided only marginal price support amid weak buying interest.
- Sufficient importer inventories enabled deferred replenishment, sustaining downward pressure on prices.
For the Quarter Ending September 2025
North America听
- In North America, the Carbamazepine Price Index fell by ~15.0% quarter-over-quarter amid stronger generic supply and softer institutional buying.
- The average Carbamazepine price for the quarter was approximately USD 45,100.80/MT, weighted by transactional volumes.
- Domestic spot prices weakened as wholesalers cleared excess lots following slower hospital and retail restocking.
- Short-term Carbamazepine Price Forecast points to consolidation at lower levels while contract negotiations reset for Q1 purchases.
- Carbamazepine Production Cost Trend eased because of lower API precursor costs and improved plant utilization from scale-ups.
- Carbamazepine Demand Outlook is steady for chronic use, but payer-managed procurement and tender cadence limited immediate volume upticks.
- The Carbamazepine Price Index saw volatility from export-import arbitrage, regional inventory rebalancing, and distributor purchasing patterns.
- Stable port throughput and trucking capacity preserved supply flow, preventing freight-driven price surges.
Why did the price of Carbamazepine change in September 2025 in North America?
- Excess regional supply and high downstream inventories prompted distributors to discount, exerting downward pressure on Carbamazepine price.
- Reduced raw-material costs and higher domestic production efficiency lowered production cost baselines, softening the Carbamazepine Price Index.
- Reliable inland and coastal logistics avoided freight premiums, allowing market fundamentals (demand/inventory) to set prices.
APAC
- In India, the Carbamazepine Price Index fell by 18.73% quarter-over-quarter, reflecting strategic supplier-led price correction.
- The average Carbamazepine price for the quarter was approximately USD 41340.23/MT, weighted by transactional volumes.
- Domestic Carbamazepine Spot Price weakened amid elevated downstream inventories and willingness to clear excess lots.
- Short term Carbamazepine Price Forecast indicates stabilization as manufacturers balance production with softer spot enquiries.
- Carbamazepine Production Cost Trend eased due to lower raw material costs and improved manufacturing efficiency.
- Carbamazepine Demand Outlook remains steady for chronic therapies, yet cautious procurement limits immediate volume growth.
- The Carbamazepine Price Index shows volatility from export flows, inventory swings and downstream purchasing patterns.
- Export competitiveness and reliable inland logistics preserved supply cadence, moderating upward pressure on domestic pricing.
Why did the price of Carbamazepine change in September 2025 in APAC?
- High downstream inventories and increased regional supply created surplus, exerting downward pressure on Carbamazepine price.
- Lower raw material costs and PLI-driven domestic output reduced production costs, softening Carbamazepine Price Index.
- Smooth inland logistics and port operations prevented freight premiums, allowing prices to reflect market demand.
Europe听
- In Europe, the Carbamazepine Price Index declined by ~12.5% quarter-over-quarter, driven by increased intra-regional supply and competitive imports.
- The average Carbamazepine price for the quarter was approximately USD 48,720.50/MT, weighted by transactional volumes.
- Spot prices softened as wholesalers and distributors destocked ahead of year-end tender cycles.
- Short-term Carbamazepine Price Forecast indicates mild stabilization with limited upside, as manufacturers align output to slower hospital tendering and private-payer delays.
- Carbamazepine Production Cost Trend eased slightly due to cheaper feedstock from Asian suppliers and modest energy cost reductions.
- Carbamazepine Demand Outlook remains stable for maintenance therapy but public-sector tender timing suppressed immediate procurement volumes.
- The Carbamazepine Price Index showed volatility from cross-border flows, currency fluctuations (EUR/USD moves), and uneven purchasing across EU members.
- Import parity and well-functioning rail/road corridors maintained supply reliability, reducing urgency-driven price spikes.
Why did the price of Carbamazepine change in September 2025 in Europe?
- Elevated inventories at distributors and delayed public tenders reduced near-term buying, putting downward pressure on Carbamazepine price.
- Cheaper imported intermediates and lower energy costs reduced production expenses, easing the Carbamazepine Price Index.
- Efficient intra-EU logistics and absence of freight bottlenecks prevented additional supply-cost pass-through to prices.
For the Quarter Ending June 2025
North America
- The Carbamazepine Spot Price in Q2 2025 reflected a bearish to stable trend that was shaped by subdued procurement from psychiatric and neurology formulation sectors. The buyers continued to draw from Q1 inventories which dampened the transactional activity in April and May.
- The Carbamazepine Price Forecast for the quarter remained conservative which was influenced by weak Q1 carryover sentiment, moderate production volumes and a general absence of seasonal demand triggers.
- In April 2025, the Price Index saw minimal movement which indicated an oversupplied market with no major logistical disruptions or feedstock shortages reported across the U.S. pharmaceutical supply chain.
- May witnessed a marginal dip in prices, attributed to limited downstream buying interest, with major generic drug producers delaying procurement amid continued API price softness globally.
- By June, steady but uninspired Carbamazepine Demand Outlook from neurological and psychiatric medicine producers, especially in contract-based supply chains, resulted in continued range-bound price movements.
- U.S.-based API importers operated with stable inventory buffers, reducing spot market exposure and preserving cash flow by avoiding speculative stockpiling during the quarter.
- The Carbamazepine Production Cost Trend remained stable in Q2, supported by consistent Chinese and Indian import flows, as no notable upstream raw material cost spikes occurred.
- The distribution network functioned efficiently across inland pharmaceutical hubs with no reported supply chain bottlenecks, eliminating cost-push inflation from logistics or warehousing.
Why did the price change in July 2025?
- Carbamazepine Spot Prices in early July 2025 showed no significant rebound due to lingering inventory excess from Q2 and continued passive procurement behaviour. Price pressure persisted as market participants awaited stronger demand cues.
- As of June 2025, the Carbamazepine Spot Price observed minimal quarterly fluctuation, consistent with broader global market sentiment.
Asia-Pacific
- The Carbamazepine Spot Price in India averaged USD 49,252.34/MT in June 2025, registering a minor uptick of 0.48% after a significant correction in May (-8.5%), driven by sentiment correction and deferred procurement resumption.
- The Carbamazepine Price Forecast in APAC during Q2 was mixed鈥攚eak in April and May, then modestly optimistic in June due to balanced inventory levels and steady downstream replenishment from psychiatric and neurological therapy manufacturers.
- April鈥檚 Price Index dipped slightly by 0.22%, reflecting moderate trade and sufficient stock levels at both manufacturing and formulation ends.
- May experienced a sharp drop in Carbamazepine Spot Prices due to weak demand and an oversupplied market. This led suppliers to adopt aggressive pricing strategies to stimulate sales amid low transaction volumes.
- June brought modest price stabilization as formulators who postponed earlier purchases returned to the market, tightening inventories marginally and supporting cautious upward movement in the Price Index.
- The Carbamazepine Production Cost Trend remained flat across Q2, supported by steady supply chains and uninterrupted production schedules with no input cost shocks.
- Logistics and inter-regional transportation remained smooth throughout the quarter, preventing any freight-induced cost volatility and enabling efficient distribution across Indian pharma hubs.
- The Carbamazepine Demand Outlook was steady across neurology, psychiatric, and limited nutraceutical applications. Veterinary offtake contributed minor but consistent support to demand.
Why did the price change in July 2025?
- Despite moderate inventory restocking in June, the Carbamazepine Spot Price in July 2025 faced resistance amid a lack of new bulk orders and subdued demand from export-facing formulation houses, limiting price momentum.
- Overall, the APAC market in Q2 reflected a sentiment-driven correction with a cautious revival phase by quarter-end, particularly in India鈥檚 API clusters.
Europe
- The Carbamazepine Spot Price in Europe mirrored global sentiment with slight softening in April and May, followed by cautious stabilization in June 2025, in response to subdued imports from Asia and modest internal demand.
- The Carbamazepine Price Forecast during Q2 remained soft-to-neutral across the continent as buyers prioritized inventory utilization over active restocking due to stagnant formulation order volumes.
- April鈥檚 Price Index edged lower due to competitive Asian offers and easing freight costs, particularly from Indian exporters trying to recover volume lost in earlier months.
- In May, EU-based buyers maintained a wait-and-watch approach as the market continued to absorb high inventory positions from Q1, creating downward pricing inertia.
- By June, spot buying activity picked up marginally across Germany and France as procurement resumed in neuropsychiatric drug manufacturing lines, although without creating strong upside risk.
- The Carbamazepine Production Cost Trend in Europe remained largely stable, supported by subdued energy cost pressures and consistent API conversion costs across EU facilities.
- Inventory levels across wholesalers and dosage manufacturers were stable, with most procurement tied to routine production schedules and minimal speculative purchases.
- The Carbamazepine Demand Outlook remained flat, particularly in generics-focused production facilities across Spain and Eastern Europe, with no promotional push or seasonal uplift observed in Q2.
Why did the price change in July 2025?
- In July 2025, Carbamazepine Spot Prices in Europe continued to remain under pressure as buyers in the EU bloc remained hesitant to scale procurement amid weak end-market signalling and stable import supply from APAC.
- By end of June 2025, European Carbamazepine Spot Prices showed marginal quarterly fluctuation and reflecting cautious regional trade behaviour.
